Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29514120 | 1.00 | DGAT1 (0.32) | DGAT1F2RL1MAPTATRATRIP | |
| SCHEMBL26720538 | 0.86 | KMT2A (0.34) | DGAT1F2RL1MAPTATRATRIP | |
| SCHEMBL17837759 | 0.86 | DGAT1 (0.32) | DGAT1F2RL1 | |
| SCHEMBL12347043 | 0.84 | DGAT1 (0.31) | DGAT1F2RL1 | |
| SCHEMBL25226076 | 0.82 | NTRK1 (0.33) | DGAT1 | |
| SCHEMBL25278687 | 0.81 | ADK (0.33) | DGAT1F2RL1 | |
| SCHEMBL30295771 | 0.81 | ADK (0.33) | DGAT1F2RL1 | |
| SCHEMBL25241902 | 0.81 | ADK (0.33) | DGAT1F2RL1 | |
| SCHEMBL31409590 | 0.80 | DGAT1 (0.32) | DGAT1F2RL1MAPT | |
| SCHEMBL22013966 | 0.79 | MAPT (0.35) | DGAT1F2RL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074881-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2025-03-06 | — | — | US | disclosed |
| US-12110276-B2 | Pyrazolo compounds and methods of use thereof | GENENTECH, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| EP-4436957-A1 | THERAPEUTIC INDAZOLE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118302411-A | Therapeutic indazole compounds and methods of use thereof for the treatment of cancer | 基因泰克公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20230339970-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| EP-4214214-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-07-26 | — | — | EP | disclosed |
| US-20230202984-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230202984-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230202984-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| WO-2023097195-A1 | THERAPEUTIC INDAZOLE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2020023393-A1 | KINASE ANTAGONISTS AND METHODS FOR MAKING AND USING THEM | BIOBLOCKS, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| EP-3233829-B1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3233829-B1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER (US) | 2019-08-14 | — | — | EP | disclosed |
| US-9593097-B2 | Axl inhibitors | PFIZER INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593097-B2 | Axl inhibitors | PFIZER INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593097-B2 | Axl inhibitors | PFIZER INC. (US) | 2017-03-14 | — | — | US | disclosed |
| WO-2016097918-A1 | PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS | PFIZER INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160176850-A1 | AXL INHIBITORS | PFIZER INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160176850-A1 | AXL INHIBITORS | PFIZER INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160176850-A1 | AXL INHIBITORS | PFIZER INC. | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074881-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | DGAT1 703/4885F2RL1 2472/4885MAPT 411/4885 |
| US-20230339970-A1 | CASEIN KINASE 1 DELTA MODULATORS | CSNK1D, CSNK1A1, CSNK1G1 | DGAT1 3129/4885F2RL1 3897/4885MAPT 336/4885 |
| US-20230202984-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | DGAT1 703/4885F2RL1 2472/4885MAPT 411/4885 |
| US-20160176850-A1 | AXL INHIBITORS | AXL, FLT3, MERTK | DGAT1 4204/4885F2RL1 1610/4885MAPT 1834/4885 |
| US-12110276-B2 | Pyrazolo compounds and methods of use thereof | THPO, KLK3, TP53 | DGAT1 3867/4885F2RL1 1561/4885MAPT 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.